Malik S T, Talbot D, Clarke P I, Osborne R, Reznek R, Wrigley P F, Slevin M L
ICRF Department of Medical Oncology, St. Bartholomew's, Hospital, London, UK.
Br J Cancer. 1990 Dec;62(6):1023-5. doi: 10.1038/bjc.1990.431.
A phase II trial of continuous oral therapy with UFT, a combination of uracil and the 5-fluorouracil analogue 1-(2-tetrahydrofuryl)-5-fluorouracil (Futraful, Ftorafur), was conducted in 40 patients with advanced colorectal cancer and 18 patients with advanced gastric cancer. Six partial responses were seen in the 36 evaluable patients with colorectal cancer (response rate 16.6%; 95% confidence limits 6.4-32.8%), and one partial response was seen in the 16 evaluable patients with gastric cancer (response rate 6%; 95% confidence limits 0.27-30.2%). The overall toxicity of the treatment was low, and all patients were treated as outpatients. The results suggest that oral UFT has comparable activity to standard regimes of 5-fluorouracil, and because of the convenience of oral administration is a useful therapy in the management of patients with advanced colorectal cancer.
对40例晚期结直肠癌患者和18例晚期胃癌患者进行了一项关于优福定（UFT，尿嘧啶与5-氟尿嘧啶类似物1-(2-四氢呋喃基)-5-氟尿嘧啶（替加氟，呋氟尿嘧啶）的组合）持续口服治疗的II期试验。在36例可评估的结直肠癌患者中观察到6例部分缓解（缓解率16.6%；95%置信区间6.4 - 32.8%），在16例可评估的胃癌患者中观察到1例部分缓解（缓解率6%；95%置信区间0.27 - 30.2%）。治疗的总体毒性较低，所有患者均作为门诊患者接受治疗。结果表明，口服优福定与5-氟尿嘧啶的标准治疗方案具有相当的活性，并且由于口服给药的便利性，它是晚期结直肠癌患者管理中的一种有用治疗方法。
